MedTrace Logo

Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg

NCT00687973 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 393

Last updated 2011-03-11

Study results available
· View outcomes & findings →

Summary

Assess that for an equivalent brachial blood pressure (BP)lowering, a fixed dose combination amlodipine/valsartan based regimen reduces central aortic BP pressure to a larger extent than an atenolol/amlodipine combination based regimen.

Conditions

Interventions

DRUG

Valsartan/amlodipine 80/5 mg tablets

DRUG

Amlodipine 5 mg capsules

DRUG

Amlodipine 10 mg capsules

DRUG

Atenolol 50 mg tablets

DRUG

Atenolol 100 mg tablets

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00687973 on ClinicalTrials.gov